Cronos Group Q4 revenue up to $5.6M but misses estimates as it posts net loss

Published Mar 27, 2019 03:54 a.m. ET
Medical marijuana is shown in Toronto on November 5, 2017. Cronos Group Inc. reported a net loss of $11.6 million in its fourth quarter compared with a profit in the same quarter a year ago, as revenue more than tripled with the legalization of recreational marijuana in Canada. The company says the loss amounted to six cents per share for the quarter ended Dec. 31. THE CANADIAN PRESS/Graeme Roy

TORONTO — Cronos Group Inc. reported an uptick in fourth−quarter revenue —  boosted by the legalization of recreational cannabis last October — but missed analyst estimates and posted a quarterly net loss.

The Toronto−based licensed producer saw revenue more than triple to $5.6 million during the three−month period ended Dec. 31, but operating expenses soared as well.

The uptick in costs was driven by an increase in research and development expenses, talent acquisition and professional and consulting fees for various strategic initiatives, Cronos said.

Its chief executive Mike Gorenstein said the company has been investing in areas of the cannabis supply chain that have long−term sustainable value, such as developing branded products and intellectual property, rather than cultivation and production capacity.

"This−focused approach is proving successful and analogous industries, such as consumer packaged goods in pharmaceuticals, and we think it will prove successful in the cannabis industry as well," he told analysts on a conference call on Tuesday.

"In other words, you can expect our focus to be on making the cheese, rather than raising and milking the cows."

Cronos stock was down as much as five per cent on the Toronto Stock Exchange to $25.85 in early trading, compared to its previous close of $27.36, but was trading at $26.92 by early afternoon.

This was Cronos’ first quarterly earnings to capture sales post legalization of adult−use cannabis on Oct. 17. Although pot producers ramped up production in the lead up to legalization, shortages of product across the country continue to linger.

Cronos’ revenues for the quarter at $5.6 million fell short of the $10.44 million expected by analysts surveyed by Thomson Reuters Eikon.

Its revenues were also below that of its peers during the latest quarter, said Owen Bennett, an analyst with Jefferies. For example, Canopy Growth Corp. and Aurora Cannabis had quarterly revenues of $83 million and $54 million, respectively, while Organigram Holdings and Hexo Corp. posted revenues of $12 million and $13 million, he said in a note to clients.

Given Cronos’ valuation — helped by a recent $2.4 billion equity investment by tobacco giant Altria Group Inc. — these results are "not exactly inspiring," he said.


Cronos did not break out recreational sales, but Bennett estimates that it totalled approximately $2.3 million during the quarter, also lower than the adult−use sales reported by peers.

"With capacity remaining limiting (in our view), its main recreational brand still receiving muted reviews, and unclear derivative infrastructure, we struggle to see how sales will materially pick up throughout 2019," Bennett said.

Cronos reported a net loss of $11.6 million during the three month period ended Dec. 31, compared to a profit of $2.1 million one year earlier. The company’s quarterly operating expenses were $12.4 million, up from $2.9 million during the fourth quarter in 2017.

For the full year, Cronos reported net revenue of $15.7 million, up $11.6 million or 285 per cent compared to $4.1 million for the full year 2017.

Earlier this month, Cronos closed the $2.4 billion equity investment by Altria, which now gives the Marlboro maker a 45 per cent stake in the licensed producer. Under that agreement, Altria can also invest up to a further $1.4 billion within four years that would increase its ownership stake in the Toronto−based pot producer to 55 per cent.

With Altria’s help, Cronos’ key priorities in the near−term are talent acquisition, product development and research and development, Gorenstein said.

Although Altria has a stake in e−cigarette maker Juul, when asked whether this could be leveraged to develop a cannabis vape device, Gorenstein said Cronos sees cannabinoids as distinct from nicotine. However, he said Altria has some innovation and expertise in tobacco that can be useful for pre−rolled cannabis.

"The (Altria) investment not only provides additional access to financial resources, but also the ability to accelerate and scale our product development and commercialization capabilities globally."

Companies in this story: (TSX:CRON)

Armina Ligaya, The Canadian Press


Related posts